Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Nivolumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Sirolimus 3Radiotherapy 3Methods 3Gemcitabine 3Early Intervention, Educational 3Drug Therapy 3Biopsy 3spartalizumab 2epacadostat 2atezolizumab 2X-Rays 2Topotecan 2Surveys and Questionnaires 2Specimen Handling 2Palliative Care 2Nuclear Medicine Department, Hospital 2Ipilimumab 2Interleukin-2 2Educational Status 2Dasatinib 2Cyclophosphamide 2Carboplatin 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Proteasome Inhibitors × Gastrointestinal × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡